Participants will be allowed as needed (PRN) benztropine (1-6mg/day) for extrapyrmidal symptoms, lorazepam (1-6 mg/day) for anxiety, agitation or akathisia, and chloral hydrate for sleep (500-1000 mg/day). To minimize the effects of the PRN medications on test results, participants will not receive any of the above PRN medications 12 hours prior to neurocognitive testing. Additionally, participants requesting the use of benztopine or any antiparkinson agent will first be assessed with a movement rating scale to document the presence of EPS prior to receiving the antiparkinson agent and will not have received any antiparkinson agent within 12 hours prior to the movement assessment. Participants requiring routine use of benztropine and lorazepam will be excluded or withdrawn from the study.